Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.

导出 LinkOut

翻译打印收藏纠错

第一作者： Lin,Tao

第一单位： Shenzhen Kivita Innovative Drug Discovery Center and the State Key Laboratory Breeding Base-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing 100084, PR China; Bioinformatics and Drug Design Group, Department of Pharmacy and Center for Computational Science and Engineering, National University of Singapore, 117543, Singapore.

作者： Lin,Tao ^[1] ; Feng,Zhu ^[2] ; Feng,Xu ^[3] ; Zhe,Chen ^[4] ; Yu Yang,Jiang ^[5] ; Yu Zong,Chen ^[6]

作者单位： Shenzhen Kivita Innovative Drug Discovery Center and the State Key Laboratory Breeding Base-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing 100084, PR China; Bioinformatics and Drug Design Group, Department of Pharmacy and Center for Computational Science and Engineering, National University of Singapore, 117543, Singapore. ^[1] Innovative Drug Research Centre and College of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, PR China. ^[2] College of Pharmacy, State Key Laboratory of Medicinal Chemical Biology and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, PR China. ^[3] Zhejiang Key Laboratory of Gastro-intestinal Pathophysiology, Zhejiang Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, No. 54 Youdian Road, Hangzhou 310006, PR China. ^[4] Shenzhen Kivita Innovative Drug Discovery Center and the State Key Laboratory Breeding Base-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing 100084, PR China. Electronic address: jiangyy@sz.tsinghua.edu.cn. ^[5] Bioinformatics and Drug Design Group, Department of Pharmacy and Center for Computational Science and Engineering, National University of Singapore, 117543, Singapore. Electronic address: phacyz@nus.edu.sg. ^[6]

关键词 Afatinib (Pubmed CID: 10184653)Anticancer Co-target Drug escape pathways Erlotinib (Pubmed CID: 176870)Gefitinib (Pubmed CID: 123631)Lenvatinib (Pubmed CID: 9823820)Multi-target Pazopanib (Pubmed CID: 10113978)Systematically XL647 (Pubmed CID: 10458325)

主题词抗肿瘤药(Antineoplastic Agents);临床试验(主题)(Clinical Trials as Topic);药物释放系统(Drug Delivery Systems);人类(Humans);肿瘤(Neoplasms)

DOI 10.1016/j.phrs.2015.09.019

PMID 26438971

发布时间 2015-12-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交